Background: Gestational diabetes mellitus (GDM) is carbohydrate intolerance first recognised throughout being pregnant and related to problems for moms and infants. Probiotics are naturally occurring micro-organisms, which when ingested in satisfactory quantities, could confer well being advantages. Proof of the function of probiotics as therapy for GDM is proscribed.

Goals: To guage the security and effectiveness of probiotics in treating girls with GDM on maternal and toddler outcomes.

Search strategies: We searched the Cochrane Being pregnant and Childbirth’s Trials Register ClinicalTrials.gov, WHO Worldwide Scientific Trials Registry Platform (ICTRP) (24 July 2019), and reference lists of retrieved research.

Choice standards: Randomised managed trials (RCTs) evaluating using probiotics versus placebo/commonplace take care of the therapy of GDM.

Information assortment and evaluation: Two overview authors independently assessed research eligibility, extracted knowledge, checked knowledge accuracy, and assessed danger of bias of included trials. The knowledge of proof for chosen maternal and toddler/baby outcomes was assessed utilizing GRADE.

Foremost outcomes: 9 RCTs (695 pregnant girls with GDM) evaluating probiotics versus placebo had been recognized. The general danger of bias within the 9 RCTs was low to unclear and the proof was downgraded for imprecision as a result of small numbers of ladies taking part within the trials. The trials had been carried out in hospitals and universities in Iran (seven trials), Thailand (one trial) and Eire (one trial). All trials in contrast probiotics with placebo. Maternal outcomes We’re unsure if probiotics have any impact in contrast with placebo on hypertensive problems of being pregnant, (danger ratio (RR) 1.50, 95% confidence interval (CI) 0.64 to three.53; individuals = 256; research = 3; low-certainty proof) and mode of beginning as caesareans (common RR 0.64, 95% CI 0.30 to 1.35; individuals = 267; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: mode of beginning as vaginal/assisted and subsequent improvement of sort 2 diabetes. We’re unsure if probiotics have any impact in contrast with placebo on induction of labour (RR 1.33, 95% CI 0.74 to 2.37; individuals = 127; research = 1; very low-certainty proof). For different secondary maternal outcomes, we’re unsure if there are variations between probiotics and placebo for: postpartum haemorrhage; weight acquire throughout being pregnant intervention and whole gestational weight acquire; fasting plasma glucose and want for further pharmacotherapy (insulin). Probiotics could also be related to a slight discount in triglycerides and whole ldl cholesterol.

In probiotics in contrast with placebo, there was proof of discount in markers for insulin resistance (HOMA-IR) and HOMA-B; and insulin secretion. There was additionally a rise in quantitative insulin sensitivity test index (QUICKI). Probiotics had been related to minor advantages in related bio-markers with proof of a discount in inflammatory markers high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and marker of oxidative stress malondialdehyde; and a rise in antioxidant whole glutathione, however we’re unsure if there may be any distinction in whole antioxidant capability. No trials reported secondary outcomes: perineal trauma, postnatal weight retention or return to pre-pregnancy weight and postnatal melancholy.

Toddler/baby/grownup outcomes We’re unsure if probiotics have any impact, in contrast with placebo, on the danger of large-for-gestational-age infants (RR 0.73, 95% CI 0.35 to 1.52; individuals = 174; research = 2; low-certainty proof) or toddler hypoglycaemia (RR 0.85, 95% CI 0.39 to 1.84; individuals = 177; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: perinatal (fetal/neonatal) mortality; or neurosensory incapacity. For different secondary outcomes, we’re unsure if there may be any distinction between probiotics and placebo in gestational age at beginning, preterm beginning, macrosomia, birthweight, head circumference, size, toddler hypoglycaemia, and neonatal intensive care unit (NICU) admissions. There was proof of a discount in toddler hyperbilirubinaemia with probiotics in contrast with placebo. No trials reported secondary outcomes: toddler adiposity, and later childhood adiposity. There have been no adversarial occasions reported by any of the trials.

Authors’ conclusions: Low-certainty proof means we’re not sure if there may be any distinction between probiotic and placebo teams in maternal hypertensive problems of being pregnant, caesareans; and large-for-gestational-age infants. There have been no adversarial occasions reported by the trials. Because of the variability of probiotics used and small pattern sizes of trials, proof from this overview has restricted means to tell observe. Nicely-designed adequately-powered trials are wanted to establish whether or not probiotics could enhance maternal blood glucose ranges and/or toddler/baby/grownup outcomes; and whether or not they can be utilized to deal with GDM.

Environmental danger evaluation related to aquatic and terrestrial contamination is usually based mostly on predicted or measured environmental concentrations of a restricted checklist of chemical substances in a restricted variety of environmental compartments. Excessive decision mass spectrometry (HRMS) can present a extra complete image of publicity to dangerous chemical substances, significantly by means of the retrospective evaluation of digitally saved HRMS knowledge. Utilizing this technique, our research characterised the contamination of varied environmental compartments together with 154 floor water, 46 city effluent, 67 sediment, 15 soil, 34 groundwater, 24 biomovie, 41 gammarid and 49 fish samples at 95 websites broadly distributed over the Swiss Plateau.

As a proof-of-concept, we targeted our investigation on antifungal azoles, a category of chemical substances of rising concern on account of their endocrine disrupting results on aquatic organisms and people. Our outcomes demonstrated the prevalence of antifungal azoles and a few of their (bio)transformation merchandise in all of the analyzed compartments (0.1-100 ng/L or ng/g d.w.). Comparability of precise and predicted concentrations confirmed the partial suitability of degree 1 fugacity modelling in predicting the publicity to azoles. Danger quotient calculations moreover revealed danger of publicity particularly if a number of the investigated rivers and streams are used for consuming water manufacturing.

Ferritin light chain antibody
10-1569	Fitzgerald	1 mg	EUR 418.8
Description: Mouse monoclonal Ferritin light chain antibody

Ferritin light chain antibody
10-1570	Fitzgerald	1 mg	EUR 418.8
Description: Mouse monoclonal Ferritin light chain antibody

Lambda Light chain Antibody
43108-100ul	SAB	100ul	EUR 302.4

Kappa Light chain Antibody
46588-100ul	SAB	100ul	EUR 302.4

Ferritin Light Chain Antibody
49643-100ul	SAB	100ul	EUR 399.6

Ferritin Light Chain Antibody
49643-50ul	SAB	50ul	EUR 286.8

Ferritin Light Chain antibody
10R-8606	Fitzgerald	100 ul	EUR 471.6
Description: Mouse monoclonal Ferritin Light Chain antibody

IgG light chain Antibody
abx140241-01mg	Abbexa	0.1 mg	EUR 427.2

lambda light chain Antibody
abx034778-400ul	Abbexa	400 ul	EUR 627.6

lambda light chain Antibody
abx034778-80l	Abbexa	80 µl	EUR 343.2

kappa light chain Antibody
abx025345-400ul	Abbexa	400 ul	EUR 627.6

kappa light chain Antibody
abx025345-80l	Abbexa	80 µl	EUR 343.2

Acrosin light chain Antibody
abx432275-200ul	Abbexa	200 ul	EUR 343.2

Ferritin Light Chain Antibody
DF6604	Affbiotech	200ul	EUR 420

Kappa light chain Antibody
DF13703	Affbiotech	100ul	EUR 420

Lambda Light chain Antibody
DF14068	Affbiotech	100ul	EUR 420

Kappa Light Chain Antibody
R20178-100UG	NSJ Bioreagents	100ug	EUR 409

Kappa Light Chain Antibody
R20178BTN-50UG	NSJ Bioreagents	50ug	EUR 409

Kappa Light Chain Antibody
R20178SAF-250UG	NSJ Bioreagents	250ug	EUR 979

Clatherin Light Chain Antibody
R33209-100UG	NSJ Bioreagents	100 ug	EUR 399

Kappa Light Chain Antibody
RQ5072	NSJ Bioreagents	100ul	EUR 419

Lambda Light Chain Antibody
V8873-100UG	NSJ Bioreagents	100ug	EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody
V8873-20UG	NSJ Bioreagents	20ug	EUR 219
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody
V8873SAF-100UG	NSJ Bioreagents	100ug	EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2624-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2624-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2624IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2624SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7424-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7424-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7424IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7424SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2145-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2145-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2145IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2145SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2146-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2146-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2146CF488-100T	NSJ Bioreagents	100 Tests	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2146IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2146SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2150-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2150-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2150CF488-100T	NSJ Bioreagents	100 Tests	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2150IHC-7ML	NSJ Bioreagents	7 ml	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2150SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

F5(Coagulation factor V light chain) Conjugated Antibody
C47757	SAB	100ul	EUR 476.4

Kappa Light Chain
10R-8329	Fitzgerald	100 ug	EUR 318
Description: Mouse monoclonal Kappa Light Chain antibody

Kappa Light Chain
A20064	ScyTek Laboratories	2 ml	EUR 94.8

Kappa Light Chain
A00064	ScyTek Laboratories	6 ml	EUR 129.6

Kappa Light Chain
A00064.0025	ScyTek Laboratories	25 ml	EUR 302.4

Human Factor X Light Chain AssayLite Antibody (FITC Conjugate)
72215-05141	AssayPro	150 ug	EUR 513.6

Rabbit Kappa light chain antibody
70R-10679	Fitzgerald	1 ml	EUR 447.6
Description: Rabbit polyclonal Kappa light chain antibody

Rabbit Lambda light chain antibody
70R-10680	Fitzgerald	1 ml	EUR 417.6
Description: Rabbit polyclonal Lambda light chain antibody

Myosin Light Chain 1 antibody
10-M22A	Fitzgerald	1 mg	EUR 330
Description: Mouse monoclonal Myosin Light Chain 1 antibody

Ferritin light chain Monoclonal Antibody
42045-100ul	SAB	100ul	EUR 399.6

igg light chain Polyclonal Antibody
42162-100ul	SAB	100ul	EUR 399.6

Ferritin light chain Polyclonal Antibody
42538-100ul	SAB	100ul	EUR 399.6

Myosin Light Chain 2 antibody
70R-37593	Fitzgerald	100 ug	EUR 327.6
Description: Rabbit Polyclonal Myosin Light Chain 2 antibody

Human Iambda light chain Antibody
48057-100ul	SAB	100ul	EUR 399.6

Human Iambda light chain Antibody
48057-50ul	SAB	50ul	EUR 286.8

Myosin light chain kinase Antibody
48846-100ul	SAB	100ul	EUR 399.6

Myosin light chain kinase Antibody
48846-50ul	SAB	50ul	EUR 286.8

Myosin Light Chain 2 Antibody
49023-100ul	SAB	100ul	EUR 399.6

Myosin Light Chain 2 Antibody
49023-50ul	SAB	50ul	EUR 286.8

Human Ferritin Light Chain Antibody
32889-05111	AssayPro	150 ug	EUR 313.2

Human Dynein light chain Antibody
33041-05111	AssayPro	150 ug	EUR 313.2

Myosin Light Chain 2 antibody
20R-1971	Fitzgerald	50 ug	EUR 337.2
Description: Rabbit polyclonal Myosin Light Chain 2 antibody

Myosin Light Chain 2 antibody
20R-2327	Fitzgerald	50 ug	EUR 337.2
Description: Rabbit polyclonal Myosin Light Chain 2 antibody

IgG (Light Chain Specific) Antibody
20-abx159553	Abbexa	EUR 326.40 EUR 276.00	100 ug 50 ug

Ig kappa Light Chain Antibody
20-abx137077	Abbexa	EUR 427.20 EUR 627.60	0.5 mg 1 mg

Ig lambda Light Chain Antibody
20-abx137078	Abbexa	EUR 427.20 EUR 627.60	0.5 mg 1 mg

Myosin Light Chain 4 Antibody
20-abx137474	Abbexa	EUR 844.80 EUR 393.60 EUR 276.00	100 ug 20 ug 5 ug

Ferritin light chain Antibody (Biotin)
20-abx105411	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin light chain Antibody (Biotin)
20-abx105412	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin Light Chain (FTL) Antibody
20-abx001467	Abbexa	EUR 493.20 EUR 710.40 EUR 218.40 EUR 376.80	100 ul 200 ul 20 ul 50 ul

Ferritin light chain Antibody (HRP)
20-abx108249	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin light chain Antibody (HRP)
20-abx108250	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin Light Chain (FTL) Antibody
20-abx109781	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin Light Chain (FTL) Antibody
20-abx109782	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin light chain Antibody (FITC)
20-abx106830	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin light chain Antibody (FITC)
20-abx106831	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ferritin Light Chain (FTL) Antibody
abx016118-100ug	Abbexa	100 ug	EUR 493.2

The case research clearly reveals that the retrospective evaluation of HRMS/MS knowledge can enhance the present information on publicity and the associated dangers to chemical substances of rising concern and may be successfully employed sooner or later for such functions. Innovation diffusion principle proposed that adopters-whether people or organizations-sometimes reinvent an innovation as they acquire expertise utilizing it. Reinvention can improve (or impede) the probability of an IS innovation’s acceptance and additional diffusion. This paper stories on a case research of BioSense, an interorganizational system that was designed as an early detection software for bio-terror assaults and subsequently modified to raised serve this want in addition to to function as a public well being system for pinpointing geographic clusters of harmful/acute illness outbreaks. By inspecting the interaction among the many political and organizational dynamics and technical properties of the BioSense system, we make clear processes affecting reinvention in an interorganizational context.